Essential Thrombocythemia & Polycythemia Vera Clinical Trials
| Drug Name (* indicates active recruitment) | JAK2 Inhibitor? | Company | Study Name | Timeline | Site Locations | For more information |
| * Anagrelide and Hydroxyurea | No | Shire Pharmaceutical Development | A Study of Anagrelide and Hydroxyurea in High-Risk ET | Opened September 2005; Est. completion September 2014 | Click here to see the 41 European locations |
866-842-5335 |
| * Erlotinib | Yes | OSI Pharmaceuticals | Trial of Erlotinib in Patients With JAK-2 V617F Positive PV | Opened December 2009; Est. completion May 2012 |
Oklahoma |
Mohamad Cherry, MD at mohamad-cherry@ouhsc.edu or 405-271-4922 Melissa Yarbrough at melissa-yarbrough@ouhsc.edu or 405-271-8777 |
|
* Familial Study of MPDs |
N/A | MPD-RC | Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes | Opened July 2006; estimated completion March 2015 | University of Utah | Dr. Josef Prchal 801-581-4220 or Kim Hickman 801-581-3707 |
| *Fludarabine | No | University of Illinois | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies | Opened February 2000; Est. completion February 2015 | Illinois |
Damiano Rondelli at drond@uic.edu Mariela Girotti at mgirotti@uic.edu |
| * Imetelstat | No | Geron | Open Label Study to Evaluate the Activity of Imetelstat in Patients With ET | Opened Dec 2010; Est. completion June 2013 | California, Florida, Illinois, Maryland, New York, S. Carolina, Texas, Germany, Switzerland | Christina Ayran at cayran@geron.com |
| * INC424 | Yes | Incyte | Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: The RESPONSE Trial | Opened October 2010; Est. completion July 2013 | Click here to see the 141 worldwide trial sites |
William Garrett at 302-498-6987 OR wgarrett@incyte.com Amy Blithe at 302-498-7079 OR ablithe@incyte.com |
| * LY2784544 | Yes | Eli Lilly and Company | A Study in MPDs | Opened April 2010; estimated completion July 2013 | Arizona, Texas, Utah | 877-CTLILLY (877-285-4559) Mon-Fri from 9 AM to 5 PM EST |
| * Pegasys | No | MPD-RC / Roche | Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) | Opened September 2011; Est. completion December 2014 | Click here for a list of 32 worldwide trial sites |
Dr. Ronald Hoffman at ronald.hoffman@mssm.edu or 212-241-2296
|
| *Pegasys | No | Odense University Hospital | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (DALIAH) | Opened January 2012; Est. completion January 2020 | Denmark |
Thomas S. Larsen at thomas.stauffer.larsen@ouh.regionsyddanmark.dk Sally Grant at sally.grant@ouh.regionsyddanmark.dk |
| * PEG-P-INF -alpha 2b (P1101) | Yes | AOP Orphan Pharmaceuticals AG | Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera (PEGINVERA) | Opened August 2010; Est. completion February 2012 | Austria |
Franz-Josef Tarmann at franz-josef.tarmann@aoporphan.com Nina Vartyan-Bohm at nina.vartyan-boehm@aoporphan.com |
| *SAR302503 | Yes | Sanofi-Aventis | Study with SAR302503 with PV and ET | Opened October 2011; Est. completion February 2015 | Kentucky, Minnesota; France, Germany, Italy, Spain | Contact-Us@sanofi-aventis.com |
| * n/a | n/a | MPD-RC | Familial Myeloproliferative Disorders | Opened March 2008; estimated completion March 2013 | D.C., Illinois, New York, Utah, Italy |
Josef Prchal at 801-585-3229 / josef.prchal@hsc.utah.edu Neeraj Ajarwal at 801-585-3229 |
| Pegasys | No | MPD-RC / Roche | Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) | Opens September 2011; Est. completion December 2015 | Click here for a list of 32 trial sites |
Dr. Ronald Hoffman at ronald.hoffman@mssm.edu or 212-241-2296 |
| Pegasys | No | Hoffman-LaRoche | Pegasys in Patients with Myeloproliferative Diseases | Opened April 2005; Est. completion in December 2017 | Texas | Srdan Verstovsek at 713-745-3429 |
| SPD422 | No | Shire Pharmaceutical Development | Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults with At Risk Essential Thrombocythemia | Opened November 2010; Est. completion October 2012 | Japan | 866-842-5335 |
| Xagrid | No | Shire Pharmaceutical Development | Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to Xagrid Compared to Other Treatments | Opened May 2005; Est. completion April 2014 | London, U.K. | 866-842-5335 |
